The Debate on Eight: Controversies in Contemporary Care for Patients with Hemophilia A:


Module 1: The Current Role of Plasma-Derived Therapies for Hemophilia A

Module 2: The Evolving and Future Role of Plasma-Derived Therapies

Release date:  Nov 27, 2019
Valid through: Nov 27, 2020

Estimated time to complete each activity: 30 minutes
Amount of credit/contact hours for each type of credit: 0.5 AMA PRA Category 1 Credit™, 0.5 ANCC contact hour per module
Media: Internet

This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and CMEology.
Postgraduate Institute for Medicine (
This activity is supported by an educational grant from Kedrion Biopharma Inc.

Target Audience
This accredited activity is designed to address the educational needs of specialists who care for patients with hemophilia A.
Educational Objectives
After completing this activity, the participant should be better able to:

  • Summarize best practices in controversial aspects of hemophilia A care
  • Identify the current, evolving, and future roles for plasma-derived FVIII
  • Apply strategies to prevent and eradicate inhibitors in patients receiving FVIII

Robert Sidonio, Jr., MD
Assistant Professor of Pediatrics and Director of Clinical Operations
Hemostasis and Thrombosis Program
Emory University School of Medicine
Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta

Guy Young, MD
Director of the Hemostasis and Thrombosis Center
Children’s Hospital Los Angeles
Professor of Pediatrics
University of Southern California Keck School of Medicine

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMEology.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Physician Continuing Medical Education The Postgraduate Institute for Medicine designates each activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.
Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity

Name of Faculty Reported Financial Relationships
Robert Sidonio, Jr., MDConsultant/Advisor: Aptevo, Bayer, Biomain, Genentech, Novo Nordisk, Octapharma, Sanofi, Takeda, and Uniqure
Fees for Non-CME/CE Services Received Directly from a Commercial Interest (eg, speakers’ bureaus): Sanofi
Research Support: Genentech, Kedrion/Grifols, Octapharma, Sanofi, and Takeda
Guy Young, MDConsultant/Advisor:  CSL Behring, Genentech, Takeda, and Uniqure
Fees for Non-CME/CE Services Received Directly from a Commercial Interest (eg, speakers’ bureaus): Genentech, Grifols, Roche, and Spark
Research Support: Genentech

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content ManagerReported Financial Relationships
Rob Lowney (CMEology)No financial relationships to disclose.
Dana Ravyn, PhD, MPH (CMEology)No financial relationships to disclose.
Beth Goodwin (CMEology)No financial relationships to disclose.
PIM planners and managersNo financial relationships to disclose.

Method of Participation During the period November 1, 2019 through November 1, 2020, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; 3) complete the post-test with a score of 75% or better with no more than 3 attempts; and 4) complete the activity evaluation.  Once you complete the online evaluation, your certificate will be made available immediately. Click on View Certificate and print the certificate for your records.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information There is no fee for this educational activity.
Policy on Privacy and Confidentiality For PIM’s policy:
For information about the activity, please contact Postgraduate Institute for Medicine ( at 1-800-423-3576 or email to